After Merck Stops Study, What Remains Of The Alzheimer's Drug Pipeline?

February 16, 2017 at 16:13 PM EST

Merck & Co, Inc. (NYSE: MRK) Tuesday reported it was halting its Phase 3 study of Alzheimer's treatment verubecestat in people ...